Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood–ocular barrier breakdown

Sakamoto, Taiji; Miyazaki, Miho; Hisatomi, Toshio; Nakamura, Toshio; Ueno, Akifumi; Itaya, Keiko; Ishibashi, Tatsuro

doi:10.1007/s00417-002-0454-2

Cited by 213 publications

(142 citation statements)

References 27 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…According to the previous clinical finding, TA fine particle suspension improved the visibility of the hyaloid and the safety of the surgical procedures during pars plana vitrectomy and also inhibited the postoperative breakdown of the blood-ocular barrier. 28 Our results also showed that it succeeded in distinguishing complete PVD, incomplete PVD, and no PVD. The same efficacy was also seen in B-scan and SEM.…”

Section: Enzymatic Vitreolysis W Chen Et Alsupporting

confidence: 66%

Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator

Huang

et al. 2007

Eye

View full text Add to dashboard Cite

Purpose To generate microplasmin (lPlm) using recombinant microplasminogen (lPlg) and recombinant tissue plasminogen activator (rt-PA) before intravitreous injection and to investigate the efficacy of lPlm in inducing posterior vitreous detachment (PVD). Methods Forty-eight female or male New Zealand white rabbits were randomized into three groups. Recombinant human lPlg was incubated with rt-PA with a 200:1 molar ratio at 371C for 40 min. The right eyes of groups 1, 2, and 3, were injected with 0.5, 1.0, and 1.5 U lPlm in 0.1 ml respectively, and 0.1 ml balanced salt solution (BSS) was injected into the left eye as controls. Scanning electron microscopy (SEM), gross specimen examination, B-ultrasonography and optical coherence tomography (OCT) were performed to detect vitreoretinal interface. Results Over eighty percent of recombinant human lPlg could be activated to active lPlm by rt-PA after 40 min incubation. Complete PVD was found at vitreous posterior pole of lPlm-treated eyes without morphological change of retina. Complete PVD of 25, 75, and 87.5% rabbit eyes was induced by 0.5, 1.0 and 1.5 U recombinant lPlm respectively on day 1. The remnants of vitreous cortex at the posterior pole were dependent on the concentration of lPlm. Among the four approaches for detecting PVD, SEM, gross specimen examination, and B-ultrasonography were more effective methods than OCT. Conclusion Intravitreous injection of 1.5 U lPlm can effectively induce complete PVD in rabbit eyes on day 1 without morphological change of retina.

show abstract

Section: Enzymatic Vitreolysis W Chen Et Alsupporting

confidence: 66%

Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator

Huang

et al. 2007

Eye

View full text Add to dashboard Cite

show abstract

“…The indications and rationale for vitrectomy, established by DRVS, have not changed substantially in recent years (Table 3.4.1), but the thresholds for performing surgery are lower due to improved surgical results from improvements in vitreoretinal instrumentation and technique 34;42;565 and the introduction of ancillary modalities [586][587][588] or modified techniques 589 . Many diabetic vitrectomy patients need fellow-eye surgery 590 .…”

mentioning

confidence: 99%

Adherence to diabetic eye examination guidelines in Australia: the National Eye Health Survey

Foreman

Keel

Xie

et al. 2017

Medical Journal of Australia

View full text Add to dashboard Cite

“…El uso de triamcinolona ha sido tema de múltiples publicaciones (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23) en donde se ha visto un beneficio tangible en la reducción del grosor macular y en algunos casos mejoría en la agudeza visual, sobretodo en los estudios iniciales (11)(12)(13)(14). En ellos, se empleó para el tratamiento de edema macular refractario a laserterapia; sin embargo, el efecto del medicamento sigue siendo temporal (20) y en muchas ocasiones se requieren reinyecciones con los riesgos que esto implica (hipertensión ocular, desprendimiento de retina, hemorragia vítrea, endoftalmitis tanto estéril como infecciosa) (29)(30)(31)(32).…”

Section: Gráf 2: Comparación Del Oct Basal Y 6 Mesesunclassified

“…Sin embargo, en muchos casos no se consigue controlar o disminuir el engrosamiento macular y los resultados visuales en el largo plazo son más bien pobres (10). Otros tratamientos empleados en años recientes, han sido: esteroides intravítreos como la triamcinolona) (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23), fármacos antiangiogénicos (bevacizumab) (24,25) y recursos quirúrgicos (vitrectomía) (26)(27)(28). Todos los anteriores empleados en forma aislada tienen sus ventajas; pero al mismo tiempo, tienen ciertos riesgos así como también efectos transitorios como en el caso de los fár-macos intravítreos (29)(30)(31)(32).…”

Section: Introductionunclassified

Uso de triamcinolona y bevacizumab en cirugía de faco-vitrectomía 25G para el tratamiento de catarata y edema macular diabético

Mota

Chacón-Lara²,

Hernández-Vázquez

2008

Arch Soc Esp Oftalmol

View full text Add to dashboard Cite

RESUMENObjetivo: Evaluar la seguridad y eficacia de la cirugía combinada de facoemulsificación y vitrectomía asistida con triamcinolona y aplicación de bevacizumab intravítreo en pacientes con catarata y edema macular diabético difuso. Pacientes y métodos: Estudio prospectivo, longitudinal, no aleatorizado, ensayo clínico no controlado. Se incluyeron trece pacientes en forma consecutiva que presentaron esencialmente catarata subcapsular posterior y edema macular difuso, a los que se les realizó cirugía de facoemulsificación, vitrectomía a tres puertos 25G asistida con triamcinolona, endofotocoagulación y aplicación de bevacizumab intravítreo. Se realizó seguimiento con medición de agudeza visual, fluorangiografía retiniana y tomografía óptica coherente (OCT) basal, a las 2 semanas, en el primer, tercero y sexto meses. Resultados: Se encontró una mejoría visual de al menos 2 líneas de visión al final del seguimiento en diez de los pacientes. En cuanto al grosor central ARTÍCULO ORIGINAL ABSTRACTObjective: To evaluate the safety and efficacy of combined phacoemulsification and triamcinoloneassisted vitrectomy with intravitreal injection of bevacizumab in patients with cataract and diffuse diabetic macular edema. Methods: In this prospective, non randomized, interventional case series we included 13 eyes of 13 patients with posterior subcapsular cataracts and diffuse macular edema who underwent phacoemulsification, 25G triamcinolone-assisted vitrectomy, endophotocoagulation and had a bevacizumab injection at the end of the procedure. The follow-up consisted of basal best corrected visual acuity, fluorescein angiography, and optical coherent tomography performed at 2 weeks, one, three and six months post-operatively. Results: An improvement in the best corrected visual acuity of at least two lines was seen in 10 of the 13 patients. The basal average central macular thickness initially was 358.23 µ (SD 50 µ) while at the end of follow-up was 216.6 µ (SD 23.2 µ).

show abstract

Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood–ocular barrier breakdown

Cited by 213 publications

References 27 publications

Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator

Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator

Adherence to diabetic eye examination guidelines in Australia: the National Eye Health Survey

Uso de triamcinolona y bevacizumab en cirugía de faco-vitrectomía 25G para el tratamiento de catarata y edema macular diabético

Contact Info

Product

Resources

About